Acoramidis Shows Promise in Reversing Cardiac Disease Progression in ATTR-CM Trial

New clinical data demonstrates that Acoramidis significantly increases days alive and free from hospitalization while reversing structural disease progression in patients with transthyretin amyloid cardiomyopathy.

30 Aug, 14:00 — 30 Aug, 14:00

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual1d ago

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM - Taiwan News

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM Taiwan News

Read full article →

Acoramidis Shows Promise in Reversing Cardiac Disease Progression in ATTR-CM Trial

Sources

Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM - Taiwan News

Related Stories

Devastating Himalayan Floods Kill Over 1,000 as Rescuers Search for Trapped Hydropower Workers

Fatal Knife Attack at New York’s Times Square Leaves One Dead, Attacker Shot by Police

Russian Strikes Kill Dozens in Kyiv Region During Sixth Consecutive Day of Attacks

U.S. Army Secretary Dan Driscoll Resigns After Clashes With Hegseth